Supplement Blueprints (supplementblueprints.com) is an independent, clinical research-driven publication dedicated to demystifying human biochemistry, evidence-based supplementation protocols, biomarker tracking, and cellular longevity science. We translate complex pharmacological trials, pharmacokinetic data, and molecular biology into actionable, high-intent protocols for high-performing adults.
Our Mission: Clinical Evidence Over Lifestyle Fluff
The modern nutritional supplement industry is saturated with proprietary blends, under-dosed formulations, and unsubstantiated marketing claims. Supplement Blueprints exists to establish an unyielding standard of scientific rigor. Every protocol published on this platform is grounded in:
- Human Randomized Controlled Trials (RCTs): Prioritizing peer-reviewed clinical data over in-vitro or rodent models.
- Exact Pharmacokinetics & Bioavailability: Detailed analysis of molecular half-lives, absorption co-factors, and optimal timing windows.
- Diagnostic Biomarker Correlation: Directly linking nutritional interventions to concrete bloodwork metrics (ApoB, HbA1c, hs-CRP, fasting insulin, homocysteine, and lipid fractionations).
- Third-Party Purity Verification: Auditing Certificate of Analysis (COA) testing, heavy metal screening, and independent laboratory certifications (e.g., Creapure®, Magtein®, Kyolic® Reserve).
Editorial Leadership & Research Board
Ryan Cole — Lead Research Analyst & Formulations Strategist
Ryan directs formulation audits, biochemical mechanism analysis, and biomarker translation at Supplement Blueprints. With an analytical background spanning metabolic bioenergetics, nootropic pharmacodynamics, and cardiovascular lipidology, Ryan specializes in deconstructing clinical literature and designing targeted, synergy-driven supplementation stacks.
Zero Commercial Bias & Transparency
Supplement Blueprints operates with absolute editorial independence. We do not accept paid editorial reviews, sponsored protocol placements, or compensation from supplement manufacturers to alter our clinical ratings. If a compound lacks robust human trial evidence, our protocol matrices reflect that reality without compromise.
For research submissions, protocol corrections, or institutional inquiries, please contact us at [email protected].